Your browser doesn't support javascript.
loading
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.
Virtakoivu, Reetta; Rannikko, Jenna H; Viitala, Miro; Vaura, Felix; Takeda, Akira; Lönnberg, Tapio; Koivunen, Jussi; Jaakkola, Panu; Pasanen, Annika; Shetty, Shishir; de Jonge, Maja J A; Robbrecht, Debbie; Ma, Yuk Ting; Skyttä, Tanja; Minchom, Anna; Jalkanen, Sirpa; Karvonen, Matti K; Mandelin, Jami; Bono, Petri; Hollmén, Maija.
Afiliação
  • Virtakoivu R; MediCity Research Laboratory, University of Turku, Turku, Finland.
  • Rannikko JH; MediCity Research Laboratory, University of Turku, Turku, Finland.
  • Viitala M; Turku Doctoral Program of Molecular Medicine, University of Turku, Turku, Finland.
  • Vaura F; MediCity Research Laboratory, University of Turku, Turku, Finland.
  • Takeda A; Turku Doctoral Program of Molecular Medicine, University of Turku, Turku, Finland.
  • Lönnberg T; MediCity Research Laboratory, University of Turku, Turku, Finland.
  • Koivunen J; MediCity Research Laboratory, University of Turku, Turku, Finland.
  • Jaakkola P; Turku Bioscience, University of Turku, Turku, Finland.
  • Pasanen A; Oulu University Hospital, MRC Oulu, Oulu, Finland.
  • Shetty S; Department of Oncology and FICAN West Cancer Centre, University of Turku and Turku University Hospital, Finland.
  • de Jonge MJA; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Robbrecht D; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Ma YT; Erasmus MC/Cancer Institute, Rotterdam, the Netherlands.
  • Skyttä T; Erasmus MC/Cancer Institute, Rotterdam, the Netherlands.
  • Minchom A; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Jalkanen S; Tampere University Hospital, Tampere, Finland.
  • Karvonen MK; Drug Development Unit, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Sutton, United Kingdom.
  • Mandelin J; MediCity Research Laboratory, University of Turku, Turku, Finland.
  • Bono P; Faron Pharmaceuticals, Turku, Finland.
  • Hollmén M; Faron Pharmaceuticals, Turku, Finland.
Clin Cancer Res ; 27(15): 4205-4220, 2021 08 01.
Article em En | MEDLINE | ID: mdl-34078651
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativação Linfocitária / Moléculas de Adesão Celular Neuronais / Receptores de Retorno de Linfócitos / Neoplasias Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativação Linfocitária / Moléculas de Adesão Celular Neuronais / Receptores de Retorno de Linfócitos / Neoplasias Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article